Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
| Revenue (TTM) | $1.14B |
| Gross Profit (TTM) | $949.42M |
| EBITDA | $-794.96M |
| Operating Margin | -23.80% |
| Return on Equity | -87.20% |
| Return on Assets | -22.20% |
| Revenue/Share (TTM) | $5.30 |
| Book Value | $3.47 |
| Price-to-Book | 36.52 |
| Price-to-Sales (TTM) | 24.24 |
| EV/Revenue | 23.81 |
| EV/EBITDA | -6.05 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 296.10% |
| Shares Outstanding | $218.38M |
| Float | $216.91M |
| % Insiders | 0.51% |
| % Institutions | 105.02% |
Volatility is currently contracting
BRIDGEWATER, N.J., Sept. 4, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 128 new employees.
— New Data Explore Efficacy and Safety of BRINSUPRI ® (brensocatib) in Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB) and History of Nontuberculous Mycobacterial (NTM) Lung Disease— —New Research Examines Treprostinil Palmitil Inhalation Powder (TPIP) via COMPERA 2.0 Risk Assessment in Pulmonary Arterial Hypertension (PAH)— BRIDGEWATER, N.J., Sept. 3, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that five abstracts highlighting data from its respiratory portfolio have been accepted for presentation at the European Respiratory Society (ERS) Congress 2026 taking place Sept.
Liquidia's Yutrepia is driving strong growth, but Insmed's Brinsupri and broader pipeline could make it the better long-term pick.
BRIDGEWATER, N.J., Aug. 26, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that management will present at the following investor conferences: 12th Annual Cantor Fitzgerald Global Healthcare Conference in New York City on Wednesday, September 9, 2026, at 8:00 a.m.
— First-in-Disease and First-in-Class Therapy Approved in Japan for Patients With Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — BRIDGEWATER, N.J., Aug. 24, 2026 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved BRINSUPRI ® (brensocatib 25-mg tablet), an oral, once-daily treatment for non-cystic fibrosis bronchiectasis (NCFB) in adults and pediatric patients 12 years and older.
Invesco Discovery Mid Cap Growth Fund had a positive return and outperformed its benchmark in the second quarter. The fund was underweight in the communication services, health care and consumer discretionary sectors. Strong stock selection and an overweight in IT added to relative return. Weakness in energy partially offset the favorable results.
INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.
Insmed NASDAQ: INSM reported second-quarter 2026 revenue growth driven by the continued launch of BRINSUPRI and steady sales of ARIKAYCE, while raising its full-year BRINSUPRI revenue outlook and increasing its long-term peak-sales estimates for its leading products.
Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript
Although the revenue and EPS for Insmed (INSM) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on INSM and any ticker you trade — then tracks every position and per-strategy win rate.
